Skip to main content

Table 3 Summary of results from MMRM and LOCF_ANCOVA in duloxetine clinical trials.

From: The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials

Outcome Frequency of significant outcomes1MMRM LOCF_ANCOVA P-value lower with MMRM LOCF_ANCOVA Outcome significant with MMRM but not LOCF_ANCOVA Outcome significant with LOCF_ANCOVA but not MMRM
HAMD 17       
   Total score 9\12 6\12 9\12 1\12 3\12 0\12
   Core subscale 9\12 8\12 5\12 3\12 2\12 1\12
   Maier subscale 10\12 9\12 6\12 2\12 2\12 1\12
   Anxiety subscale 6\12 5\12 7\12 3\12 2\12 1\12
   Retardation subscale 8\12 6\12 6\12 3\12 4\12 2\12
   Sleep subscale 1\12 1\12 10\12 2\12 0\12 0\12
MADRS Total score 5\10 3\10 7\10 2\10 2\10 0\10
HAMA Total score 3\10 3\10 4\10 5\10 0\10 0\10
CGI-Severity 6\12 6\12 8\12 2\12 0\12 0\12
CGI-Improvement 1\2 1\2 2\2 0\2 0\2 0\2
PGI-Improvement 9\12 7\12 8\12 2\12 2\12 0\12
Somatic Symptom Inventory       
   26-item Average score 2\10 2\10 7\10 3\10 0\10 0\10
   28-item Average score 3\10 2\10 7\10 3\10 1\10 0\10
VAS Pain Severity       
   Overall pain 3\10 4\10 2\10 8\10 1\10 2\10
   Headaches 1\10 0\10 5\10 5\10 1\10 0\10
   Back pain 2\10 2\10 6\10 4\10 1\10 1\10
   Shoulder pain 2\10 1\10 3\10 6\10 2\10 1\10
   Daily activities 1\10 0\10 2\10 8\10 1\10 0\10
   Pain while awake 2\10 2\10 5\10 5\10 1\10 1\10
QLDS Total score 1\4 2/4 1\4 2\4 0\4 1\4
Totals 84\202 70\202 110\202 69\202 25\202 11\202
  1. 1. Some of the eight trials included more than one dose arm. Therefore, an individual outcome could be assessed in as many as 12 comparisons with placebo.